AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2179479
Drug: multidrug chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multidrug chemotherapy schedule with VM26 and AraC
Trial: 2179479
Drug: multidrug chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multidrug chemotherapy schedule without VM26 and AraC
Trial: 7428403
Drug: Prophylactic cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic cephazolin sodium (1 g) given intramuscularly
Trial: 7428403
Drug: Prophylactic cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic cephazolin sodium (1 g) given intravenously
Trial: 29259061
Drug: Guided physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided physical exercise and dietary therapy
Trial: 28374645
Drug: Bromocriptine-QR (B-QR)
RxNorm normalized name: QR-313
DrugBank: QR-313 (DB17867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine-QR (B-QR) in high-dose insulin subset
Trial: 25896104
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 5 mg twice daily for three days
Trial: 25896104
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules for three days)
Trial: 24075920
Drug: rHA 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA 45 μg
Trial: 24075920
Drug: rHA 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA 45 μg with GLA/SE
Trial: 24075920
Drug: rHA 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA 15 μg with GLA/SE
Trial: 19059175
Drug: Monthly simulated
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly simulated and critiqued oral examinations (MSCE) from 2003 to 2006 classes
Trial: 12239234
Drug: Omapatrilat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (40 or 80 mg)
Trial: 12215465
Drug: Fosinopril/Hydrochlorothiazide (FOS/HCTZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril/Hydrochlorothiazide (FOS/HCTZ; 20 and 12.5 mg)
Trial: 7725767
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 intracervical gel
Trial: 7725767
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PGE2 vaginal tablet
Trial: 2175140
Drug: beta-endorphin infusion
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-endorphin infusion at 1 microgram.kg‐1.min‐1
Trial: 2175140
Drug: placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline) infusion
Trial: 2175140
Drug: beta-endorphin infusion
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-endorphin infusion
Trial: 29068865
Drug: Army Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Army Preparation Drill (PD)
Trial: 24405833
Drug: Adalimumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (20 mg/0.8 ml for patients <30 kg or 40 mg/0.8 ml for patients ≥30 kg, subcutaneous injection every 2 weeks)
Trial: 24405833
Drug: Placebo (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.8 ml as appropriate according to body weight, subcutaneous injection every 2 weeks)
Trial: 17709835
Drug: Low-dose multi-detector
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multi-detector row CT (30 mAs, 16 detector rows, 0.75-mm section thickness)
Trial: 17709835
Drug: Low-dose multi-detector
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multi-detector row CT
Trial: 15188172
Drug: KLH feeding
RxNorm normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLH feeding (50 and 250 mg) before immunization and booster in normal controls (n = 21)
Trial: 15188172
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration in patients with Crohn's disease (n = 12)
Trial: 15188172
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration in patients with ulcerative colitis (n = 13)
Trial: 11552143
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment interventions
Trial: 9688443
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of ticlopidine (1500 mg followed by 250 mg twice daily)
Trial: 9688443
Drug: Standard ticlopidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ticlopidine treatment (250 mg twice daily)
Trial: 2642691
Drug: Intravenous clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clomipramine hydrochloride (200 mg) and placebo tablets
Trial: 2642691
Drug: Oral clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clomipramine hydrochloride (200 mg) and isotonic saline infusion
Trial: 21527582
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D levels <25 nmol/L
Trial: 19160533
Drug: Eskimo Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eskimo Skin Care (oral oil formulation rich in natural stable fish oil)
Trial: 9165969
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tetrahydrocannabinol daily in five doses during active weeks
Trial: 27934805
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 400 µg/day for 2 months
Trial: 27934805
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 400 µg/day for 2 months
Trial: 20234138
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding tube (5-Fr) for 12 hours
Trial: 16095140
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for house dust mites (HDMs)
Trial: 2865153
Drug: Lipophilic beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipophilic beta-blockers (metoprolol and propranolol)
Trial: 18541129
Drug: Generic orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic orlistat (Ranbaxy Laboratories) 120 mg, 3 times daily for 10 days
Trial: 18541129
Drug: Innovator orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator orlistat (Xenical, Roche Laboratories) 120 mg, 3 times daily for 10 days
Trial: 26541531
Drug: Baseline (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (before treatment)
Trial: 15969876
Drug: FEX 180
RxNorm normalized name: fexofenadine hydrochloride 180 MG [Wal-Fex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEX 180 mg immediate-release tablet and PSE 240 mg extended-release tablet (control)
Trial: 8952866
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day for one month
Trial: 8952866
Drug: Fluvastatin (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (exact dosage not specified) for one month
Trial: 29666135
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy followed by radical radiotherapy (RRT) and stereotactic ablative radiotherapy (SABR) to the primary tumour and SABR/stereotactic radiosurgery (SRS) to all other metastatic sites
Trial: 29666135
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy followed by RRT/SABR
Trial: 17379046
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) tramadol 200 mg every morning plus placebo immediate-release (IR) tramadol 50 mg every 4 to 6 hours PRN rescue
Trial: 17379046
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) tramadol
Trial: 2226729
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside (HD Ara-C) with mitoxantrone (MTX)
Trial: 2226729
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside (HD Ara-C) with m-amsacrine (AMSA)
Trial: 23644930
Drug: 0.5 mg/month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/month IV ibandronate
Trial: 23644930
Drug: 1 mg/month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/month IV ibandronate
Trial: 23644930
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day oral risedronate
Trial: 21269298
Drug: Frovatriptan (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan (5.0 mg)
Trial: 16941972
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of Antongding Injectio
Trial: 9183333
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (low fixed dose warfarin plus aspirin)
Trial: 23291425
Drug: NeuroFlo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroFlo therapy
Trial: 16830143
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg intravenously every 3 months for 12 months
Trial: 8138867
Drug: Treatment instituted
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment instituted at bedtime
Trial: 29127813
Drug: Culturally Sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Sensitive Collaborative Treatment (CSCT)
Trial: 26802916
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy management (MTM) intervention targeting FRIDs
Trial: 20349201
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (specifics not provided)
Trial: 19167586
Drug: Tizanidine 6-mg
RxNorm normalized name: tizanidine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine 6-mg capsule administered intact
Trial: 19167586
Drug: Tizanidine capsule
RxNorm normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine capsule contents sprinkled in applesauce
Trial: 16520204
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA)
Trial: 19641359
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg/day)
Trial: 21617983
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg/day) + Tolterodine (2 mg/day)
Trial: 12534446
Drug: Iloprost administered
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost administered for 5 days in SSc patients
Trial: 9842825
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil and morphine combined with bupivacaine
Trial: 9842825
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (IV)
Trial: 8017740
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg enoxaparin every 12 hours
Trial: 30149414
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (control)
Trial: 27471836
Drug: Laparoscopic uterine
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laparoscopic uterine artery occlusion in combination with laparoscopic myomectomy (LUAO+LM)
Trial: 18786762
Drug: Treatment-Based Classification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-Based Classification (TBC)
Trial: 15824161
Drug: 200 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/wk oral oltipraz
Trial: 12451428
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (250 ml) with diltiazem (120 mg)
Trial: 12451428
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with diltiazem (120 mg)
Trial: 10511903
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for initial treatment of bacterial complications of acute respiratory tract viral infections
Trial: 7713831
Drug: Melatonin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin administration (100 mg at 0800)
Trial: 26696199
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy (ST)
Trial: 23332481
Drug: Behavioral health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral health music therapy intervention
Trial: 21865716
Drug: Nasal submucosal
RxNorm normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal submucosal administration of α‐GalCer‐pulsed DCs
Trial: 17503545
Drug: Structured group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured group reminiscence therapy (8 sessions, 1 session per week)
Trial: 6840159
Drug: Nifedipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (all doses)
Trial: 26386560
Drug: wPTX (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wPTX (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Trial: 23982995
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 1 mg
Trial: 3310158
Drug: Diltiazem 5
RxNorm normalized name: dilTIAZem 5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 5 mg
Trial: 9806261
Drug: 6% hydroxyethyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyle starch solution (HES)
Trial: 18200389
Drug: Dialectic‐didactic method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectic‐didactic method therapy (40 sessions) for research group (RG)
Trial: 11157185
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily for 14 days
Trial: 1836920
Drug: Plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived hepatitis B vaccine
Trial: 28333301
Drug: Total cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cholesterol ≥200 mg/dl
Trial: 28333301
Drug: Low HDL-C
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low HDL-C <50 mg/dl
Trial: 28333301
Drug: Elevated triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated triglycerides ≥150 mg/dl
Trial: 25113095
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (30 × 0.5 mg)
Trial: 22296762
Drug: Counting pills
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counting pills method (Intervention group)
Trial: 22296762
Drug: Counting pills
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counting pills method (Control group)
Trial: 15101854
Drug: Peritoneal dialysis
RxNorm normalized name: Peritoneal dialysis solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal dialysis fluid infusion (2000 ml)
Trial: 9635370
Drug: Granulocyte colony
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte colony stimulating factor (G‐CSF) therapy
Trial: 9635370
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell factor (SCF) therapy
Trial: 2805603
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (NPD) 1 g/kg ideal body weight
Trial: 2805603
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD) 0.5 g/kg ideal body weight
Trial: 29369454
Drug: 10-day concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day concomitant therapy (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg twice daily)
Trial: 29369454
Drug: 14-day PAM-B
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day PAM-B therapy (rabeprazole 20 mg, amoxicillin 1 g, metronidazole 750 mg, tripotassium dicitrato bismuthate 600 mg twice daily)
Trial: 27373556
Drug: Bushen capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen capsule
Trial: 25467540
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural self-help treatment consisting of 14 modules over 8 weeks with weekly email feedback from a clinical psychologist.
Trial: 25467540
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group receiving treatment after 8 weeks.
Trial: 18312060
Drug: Levetiracetam 500
RxNorm normalized name: levetiracetam 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 500 mg/day to 3000 mg/day
Trial: 15881484
Drug: Daytime administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytime administration of miconazole nitrate 1200 mg vaginal ovule
Trial: 12657915
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg nefopam hydrochloride solution
Trial: 26931055
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg daily) plus NAC (2000 mg daily)
Trial: 26931055
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg daily) plus placebo
Trial: 24686045
Drug: Perineural saline/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural saline/2 mL with 50 mL normal saline
Trial: 24686045
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 8 mg/2 mL
Trial: 22271538
Drug: Waitlist, no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist, no treatment control
Trial: 18381573
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 2 mg/d subcutaneously for 8 weeks
Trial: 7860757
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at 1.0 mU/kg-1 per min-1
Trial: 7860757
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (both low and high)
Trial: 19684522
Drug: Outpatient oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient oral ofloxacin 7.5 mg/kg 12 hourly and amoxycillin‐clavulanate 12.5 mg/kg 8 hourly
Trial: 19684522
Drug: Outpatient intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient intravenous (IV) ceftriaxone 75 mg/kg and amikacin 15 mg/kg once daily
Trial: 19684522
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and IV arms
Trial: 15040503
Drug: Medroxyprogesterone 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone 30 mg twice daily